VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Bekaii-Saab on Expanding Landscape in CRC

Tanios Bekaii-Saab, MD
Published: Wednesday, Mar 01, 2017



Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the expanding treatment landscape of colorectal cancer (CRC).

The armamentarium in CRC is expanding; moreover, agents across multiple lines of therapy are becoming available for patients and, overall, improving their survival, Bekaii-Saab explains. It is very important to understand sequencing of therapies, he adds. This is a major question currently among the CRC community.

In the second-line setting, there are 2 agents available: regorafenib (Stivarga) and TAS-102. The optimal sequence of these agents in the second-line setting is still unknown, he adds.


Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the expanding treatment landscape of colorectal cancer (CRC).

The armamentarium in CRC is expanding; moreover, agents across multiple lines of therapy are becoming available for patients and, overall, improving their survival, Bekaii-Saab explains. It is very important to understand sequencing of therapies, he adds. This is a major question currently among the CRC community.

In the second-line setting, there are 2 agents available: regorafenib (Stivarga) and TAS-102. The optimal sequence of these agents in the second-line setting is still unknown, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x